Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
BMC Cancer
; 21(1): 904, 2021 Aug 07.
Article
in En
| MEDLINE
| ID: mdl-34364385
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pyridines
/
Carcinoma, Renal Cell
/
Biomarkers, Tumor
/
Everolimus
/
Kidney Neoplasms
/
Anilides
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
BMC Cancer
Journal subject:
NEOPLASIAS
Year:
2021
Document type:
Article
Affiliation country:
United kingdom
Country of publication:
United kingdom